Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 8—August 2022
Dispatch

Effectiveness of Naturally Acquired and Vaccine-Induced Immune Responses to SARS-CoV-2 Mu Variant

Edmilson F. de Oliveira-Filho1, Bladimiro Rincon-Orozco1, Natalia Jones-Cifuentes, Brigitte Peña-López, Barbara Mühlemann, Christian Drosten, Andres Moreira-Soto, and Jan Felix DrexlerComments to Author 
Author affiliations: Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Virology, Berlin, Germany (E.F. de Oliveira-Filho, B. Mühlemann, C. Drosten, A. Moreira-Soto, J.F. Drexler); Universidad Industrial de Santander School of Medicine, Bucaramanga, Colombia (B. Rincon-Orozco, N. Jones-Cifuentes, B. Peña-López); German Centre for Infection Research, Berlin (B. Mühlemann, C. Drosten, J.F. Drexler)

Main Article

Table 1

Median age and days after the second dose of vaccinated persons, by vaccine type, at time of sampling among persons in Colombia*

Vaccine groups Days after second dose (range) Age, y (range)
AstraZeneca 146 (129–173) 66.0 (61–72)
Pfizer-BioNTech 99.5 (65–170) 44.6 (27–65)
Sinovac 46.0 (23–131) 44.5 (23–92)

*AstraZeneca (AZD1222), https://www.astrazeneca.com; Pfizer-BioNTech (BNT162b2), https://www.pfizer.com; Sinovac (CoronaVac), http://www.sinovac.com.

Main Article

1These first authors contributed equally to this article.

Page created: June 03, 2022
Page updated: September 08, 2022
Page reviewed: September 08, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external